Laminar Pharmaceuticals Report issue

For profit Phase 2
Founded: Palma Spain (2006)
Status: Acquired by Johnson and Johnson (2023)

Organization Overview

First Clinical Trial
2020
NCT04299191
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Laminar, Inc. | Laminar Pharmaceuticals | Laminar Pharma Inc

Active Ingredients

Drugs in Phase 2 Trials (1)

2-hydroxyoleic acid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glioma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1